The study met its primary endpoint with a significant gastrointestinal overall response rate at Day 28 of 62% and demonstrates the unprecedented efficacy of MaaT013 as third-line treatment of...
Article 223-16 of the General Regulations of the Financial Markets Authority (AMF - Autorité des Marchés Financiers) Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a...
MaaT Pharma to host a KOL webinar on December 17th, 2024, to discuss data and the unmet medical need in acute Graft-versus-Host Disease (aGvHD) - Register here. Sustained High Response Rates at...
MaaT Pharma organise un webinaire avec des experts le 17 décembre 2024 pour détailler les données et échanger sur les besoins médicaux non satisfaits dans la maladie aiguë du greffon contre...
Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.26 | 3.25 | 8 | 8.3 | 7.94 | 7880 | 8.08879086 | DE |
4 | 0.34 | 4.29292929293 | 7.92 | 9.96 | 7.88 | 10610 | 8.50924697 | DE |
12 | 0.82 | 11.0215053763 | 7.44 | 9.96 | 7.2 | 5477 | 8.27596548 | DE |
26 | 0.86 | 11.6216216216 | 7.4 | 9.96 | 6.8 | 3109 | 8.07906092 | DE |
52 | 1.46 | 21.4705882353 | 6.8 | 9.96 | 6.52 | 2437 | 8.10146374 | DE |
156 | -3.74 | -31.1666666667 | 12 | 13.55 | 4.5 | 1453 | 8.2695408 | DE |
260 | -5.24 | -38.8148148148 | 13.5 | 14.4 | 4.5 | 1611 | 9.07899805 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.